Marksans Pharma Limited — Updates, 12-11-2024: Press Release

Marksans Pharma Ltd. has reported strong financial results for the quarter and half-year ending September 30, 2024. Operating revenue increased by 21% year-over-year, reaching ₹641.9 crore, driven by substantial gains in key markets, especially the US, which grew by 33.5% year-over-year. The gross margin expanded significantly by 732 bps to 59.7%, with gross profit at ₹383.5 crore, reflecting improved product mix and favorable raw material prices. EBITDA saw a rise to ₹135.7 crore, up 19.1%, with an EBITDA margin of 21.1%. Diluted EPS increased by 15.8% year-over-year to ₹2.1.

The company is focusing on growth initiatives, including 32 products in the pipeline, new market launches, and significant capital investment of ₹76 crore to enhance its manufacturing capabilities. With cash reserves of ₹657 crore and a positive outlook driven by new launches and market share improvements, Marksans Pharma remains well-positioned for growth in the coming quarters. Investors should note the robust trajectory and continue to watch for developments in upcoming launches and market trends.